Merck Gets Positive EU CHMP Opinion to Expand ENFLONSIA RSV Use
The EU CHMP backed expanding ENFLONSIA (clesrovimab) to prevent RSV lower respiratory tract disease in at-risk children through a second season.
The EU CHMP backed expanding ENFLONSIA (clesrovimab) to prevent RSV lower respiratory tract disease in at-risk children through a second season.